NewsBenzingaIovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results Benzinga 2026.10.29 11:21 (GMT+0) Open on Benzinga Other news Hyatt Bets on Luxury, Wins Big and Raises 2026 Growth Outlook Stifel Maintains Hold on Avantor, Raises Price Target to $18 BTIG Maintains Buy on Fortinet, Lowers Price Target to $186 Stifel Maintains Hold on Automatic Data Processing, Raises Price Target to $305 Bunge Expects Multi-Oil Refinery In The Netherlands To Start Up In Q1 2027; Expects To Use More Working Capital Than The Prior Year; Brazil Currency Moves Since Election Lowered Some Costs, Increased Farmer Selling Scott Bessent Brushes Off Concerns Over AI Debt Amid CoreWeave Slump, Calls Neoclouds a ‘Small Component’
Bunge Expects Multi-Oil Refinery In The Netherlands To Start Up In Q1 2027; Expects To Use More Working Capital Than The Prior Year; Brazil Currency Moves Since Election Lowered Some Costs, Increased Farmer Selling
Scott Bessent Brushes Off Concerns Over AI Debt Amid CoreWeave Slump, Calls Neoclouds a ‘Small Component’
